We showed that K2 competes with the mAb avelumab for binding to PD-L1, allowing head-to-head comparison of the ability of K2 and avelumab to enhance T cell activation by dendritic cells and tumor cell killing by T cells.16 Here, CD274 is linked to neoplasm.